EFFECTIVENESS OF THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE: EMERGING DATA FROM INVASIVE PNEUMOCOCCAL DISEASE, PNEUMONIA, ACUTE OTITIS MEDIA AND NASOPHARYNGEAL CARRIAGE
https://doi.org/10.15690/pf.v9i3.315
Abstract
A new WHO position paper has been published recently stressing the high priority of the inclusion of PCVs in childhood immunization programs worldwide. Planning for national use of pneumococcal vaccines should take besides other factors the distribution of pneumococcal serotypes in different age groups into consideration. In addition to the serotypes included in PCV7, PCV13 contains serotypes 1, 3, 5, 6A, 7F and 19A and this vaccine provides the broadest serotype coverage of PCVs globally. In Europe and the US, the vaccine was approved in late 2009 and early 2010, respectively. Only two years after introduction of PCV13 introduction into many NIPs globally, vaccine effectiveness for the PCV13 serotypes has been documented for several clinical outcomes (invasive pneumococcal disease (IPD), including sepsis/bacteremia and acute meningitis, community-acquired pneumonia, and acute otitis media) and nasopharyngeal carriage from several countries (USA, England and Wales, Germany, Spain, Uruguay, Israel). Moreover, serotype-specific effectiveness has been demonstrated for serotypes 1, 6A, 7F and 19A, which were the most prevalent and emerging serotypes pre-PCV13 immunization.
About the Authors
Ralf Rene Reinert
Pfizer Vaccines, Collegeville, USA
United States
United States
Bulent Taysi
Pfizer Vaccines, Collegeville, USA
United States
United States
References
1. WHO. Pneumococcal conjugate vaccine for childhood immunization? WHO position paper. Wkly Epidemiol Rec. 2007; 82 (12): 93-104.
2. O'Brien K.L., Wolfson L.J., Watt J.P. et al. Burden of disease caused by streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009; 374 (9693): 893-902.
3. Musher D.M. Infections caused by streptococcus pneumoniae: clinical spectrum, pathogenesis, immunity and treatment. Clinical Infectious Diseases. 1992; 14 (4): 801-807.
4. WHO. Pneumococcal vaccines ? WHO position paper – 2012. Wkly Epidemiol Rec. 2012; 14: 129–144.
5. Reinert R.R., Paradiso P., Fritzell B. Advances in pneumococcal vaccines: the 13-valent pneumococcal conjugate vaccine received market authorization in Europe. Expert Rev Vaccines. 2010; 9 (3): 229-236.
6. Paradiso P.R. Advances in pneumococcal disease prevention: 13-valent pneumococcal conjugate vaccine for infants and children. Clin Infect Dis. 2010; 52 (10): 1241-1247.
7. FDA. 2010. [cited; Available from]. URL: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm201741.htm
8. WHO. Pneumococcal conjugate vaccines: recommendations for the production and control of pneumococcal conjugate vaccines WHO Technical report series, No. 927, Annex 2. 2005. [cited; Available from]. URL: http://www.who.int/biologicals/publications/trs/areas/vaccines/pneumo/en/index.html
9. Feavers I., Knezevic I., Powell M., Griffiths E. Challenges in the evaluation and licensing of new pneumococcal vaccines. 7-8 July 2008, Ottawa, Canada. Vaccine. 2009; 27 (28): 3681-3688.
10. Isaacman D.J., McIntosh E.D., Reinert R.R. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int J Infect Dis. 2010; 14 (3): 197-209.
11. Pilishvili T., Lexau C., Farley M.M. et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010; 201 (1): 32-41.
12. Reinert R., Jacobs M.R., Kaplan S.L. Pneumococcal disease caused by serotype 19A: review of the literature and implications for future vaccine development. Vaccine. 2010; 28 (26): 4249-4259.
13. McIntosh E.D., Reinert R.R. Global prevailing and emerging pediatric pneumococcal serotypes. Expert Rev Vaccines. 2010; 10 (1): 109-129.
14. Jauneikaite E., Jefferies J.M., Hibberd M.L., Clarke S.C. Prevalence of streptococcus pneumoniae serotypes causing invasive and non-invasive disease in South East Asia: A review. Vaccine. 2012 Apr 1.
15. Johnson H.L., Deloria-Knoll M., Levine O.S. et al. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med. 2010; 7 (10).
16. Fitzwater S.P., Chandran A., Santosham M., Johnson H.L. The worldwide impact of the seven-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2012; 31 (5): 501-508.
17. Schuchat A., Bell P.B. Monitoring the impact of vaccines postlicensure: new challenges: role of surveillance in evaluating vaccine performance. Medscape View Article. 2012. URL: http://www.medscape.com/viewarticle/576711_7
18. Miller E., Andrews N.J., Waight P.A. et al. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine. 2011; 29 (49): 9127-9131.
19. Andrews N., Kaye P., Slack M. et al. Effectiveness of the 13-valent pneumococcal conjugate vaccine against IPD in England and Wales. International symposium on pneumococci and pneumococcal diseases, ISPPD-8. 11-15 March, 2012. Iguacu Falls, Brazil. Poster 148. 2012.
20. Moore M. G1-538. Early impact of 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease among children <2 years old, U.S, 2010. 51 ICAAC. Chicago. 2011.
21. Moore M., Link-Gelles R., Farley M. et al. Impact of 13-valent pneumococcal conjugate vaccine (PCV13) on invasive pneumococcal disease (IPD), US, 2010-2011. International symposium on pneumococci and pneumococcal diseases, ISPPD-8; 11-15 March 2012. Iguacu Falls, Brazil. Poster 179. 2012.
22. Cox C.M. Early impact of the 13-valent pneumococcal conjugate vaccine (PCV13) on invasive pneumococcal disease USA 2010–2011. National immunization conference, March 26 2012. Atlanta, GA. Paper 30196. 2012. URL: http://cdc.confex.com/cdc/nic2012/webprogram/Paper30196.html
23. Van der Linden M., Imohl M. Epidemiologie invasiver Pneumokokkenerkrankungen bei kindern in Deutschland von 1997-2012: Effekte nach einfuhrung der pneumokokken-konjugatimpfung. Jahrestagung der Deutschen gesellschaft fur padiatrische infektiologie (DGPI). 19.04.-21.04.2012. Mannheim, Germany. Poster. 2012.
24. Picazo J., Ruiz-Contreras J., Casado-Flores J. et al. First impact data of 13-valent pneumococcal conjugate vaccine (PCV13) on invasive pneumocococcal disease in children in Madrid, 2010-2011 (HERACLES study). International symposium on pneumococci and pneumococcal diseases, ISPPD-8. 11-15 March 2012. Iguacu Falls, Brazil. Poster 189. 2012.
25. Picazo J., Ruiz-Contreras J., Casado-Flores J. et al. Serotype distribution of invasive pneumocococcal disease cases after the introduction of 13 valent pneumococcal conjugate vaccine (PCV13) in children in Madrid. International symposium on pneumococci and pneumococcal diseases, ISPPD-8. 11-15 March 2012. Iguacu Falls, Brazil. Poster 190. 2012.
26. Pirez M.C., Algorta G., Cedres A. et al. Impact of universal pneumococcal vaccination on hospitalizations for pneumonia and meningitis in children in Montevideo, Uruguay. Pediatr Infect Dis J. 2010; 30 (8): 669-674.
27. Machado M., Kouyoumdjian G., Marquez S. et al. Complicated pneumonia in children 0-14 years of age after the introduction of pneumococcal conjugated vaccines (PCV7/13) hospital pereira Rossell-Uruguay 1/1/2010-31/9/2011. Presented at the 8th international symposium on pneumococci and pneumococcal diseases, March 11?15, 2012. Iguacu Falls, Brazil. 2012.
28. Hortal M., Estevan M., Laurani H. et al. Decline in pediatric pneumonia hospitalizations following PCV7 and PCV13 introduction in Uruguay. Presented at the 8th international symposium on pneumococci and pneumococcal diseases, March 11-15, 2012. Iguacu Falls, Brazil. 2012.
29. Spencer D. et al. Complicated pneumonia in children. Presented at the 29th annual meeting of the European society of pediatric infectious diseases, June 7-11 2011. The Hague, Netherlands. 2011.
30. Pichichero M.C., Casey J.R., Center K. et al. Efficacy of PCV13 in prevention of AOM and NP colonization in children. First year of data from the US. Presented at the 8th international symposium on pneumococci and pneumococcal diseases, March 11-15, 2012. Iguacu Falls, Brazil. 2012.
31. Dagan R., Patterson S., Juergens C. et al. The efficacy of the 13-valent pneumococcal conjugate vaccine (PCV13). Additional serotypes on nasopharyngeal colonization: A randomized double-blind pediatric trial. Presented at the 8th international symposium on pneumococci and pneumococcal diseases, March 11-15, 2012. Iguacu Falls, Brazil. 2012.
32. Cohen R., Levy C., Bingen E. et al. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media. Pediatr Infect Dis J. 2012; 31 (3): 297-301.
Review
For citations:
Reinert R., Taysi B. EFFECTIVENESS OF THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE: EMERGING DATA FROM INVASIVE PNEUMOCOCCAL DISEASE, PNEUMONIA, ACUTE OTITIS MEDIA AND NASOPHARYNGEAL CARRIAGE. Pediatric pharmacology. 2012;9(3):8-11. https://doi.org/10.15690/pf.v9i3.315
Views:
651
Email this article 